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Tumour angiogenesis: Hitting cancer where it hurts
Kavitha Sunassee and Richard Vile
Two recent studies that involve perturbing tumour blood
supply provide new hope for anti-cancer therapies. The
first uses elegant molecular engineering to achieve
tumour-specific blood clots and the second reports the
identification of a natural inhibitor, endostatin, which is
produced from tumour extracellular matrix.
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Tumorigenesis is a complex and multi-factorial process. In
the first instance, it requires the accumulation of a series of
genetic mutations within preneoplastic cells which
uncouple the cells’ normally highly interdependent pro-
grammes of growth and differentiation. But oncogenic
mutations cannot liberate the expanding tumour popula-
tion from the need to supply itself with nutrients and
oxygen, which must come from a nearby blood supply.
Thus, it has become clear that a growing tumour needs to
stimulate not only its own cells’ growth but also growth of
infiltrating blood vessels, expansion of which is critical for
the nourishment of the tumour. The process of stimulating
growth of the vasculature is called angiogenesis, and its
central significance for tumorigenesis is underscored by
the large numbers of angiogenic factors that are now
known to be produced by tumours [1]. Indeed, in the
absence of angiogenesis, no tumour can grow larger than
1–2 mm in diameter, and the degree of vascularization of a
tumour can be one of the most reliable prognostic
indicators of clinical outcome in several tumour types [2].
The proven ability of tumours to supply their own
nutritional requirements by promoting angiogenesis has
depressing clinical implications — as it means that tumours
can grow in size without outstripping their nutritional
requirements. But the fact that tumours need to promote
angiogenesis offers distinct opportunities for therapy.
Tumours of many diverse histological types must induce
angiogenesis to survive, and the angiogenic pathways used
are, for the most part, independent of tumour type. So,
whereas different tumours show widely differing suscepti-
bilities to conventional anti-cancer therapies, such as
chemotherapy and radiotherapy, an effective anti-angio-
genic therapy might have wide-spectrum applicability as a
general anti-cancer treatment.
Attractive as they are as intervention therapies, anti-
angiogenic strategies must still be developed which do not
interfere pathologically with the normal angiogenic
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Induction of a blood clot specifically in tumour blood vessels, as described by Huang et al. [3].  (a) Tissue factor is active only when part of a
membrane-associated complex. (b) Soluble tissue factor has limited activity, unless it is anchored to the membrane by association with the
bispecific antibody that also recognizes the MHC class II molecule expressed only on the surface of tumour endothelial cells. 
requirements of the body. One elegant method by which
tumour-specific angiogenesis might be therapeutically tar-
geted has recently been described by Philip Thorpe’s
group [3]. These workers reasoned that an effective way to
kill a tumour would be to induce a thrombosis (blood clot)
at the tumour site. They focused on a key molecule
involved in the coagulation process, tissue factor (TF),
which initiates the blood clotting cascade. Normally, tissue
factor associates with another clotting factor, Factor
VII/VIIa, to activate serine proteases which themselves lead
to thrombin production and the formation of a blood clot
(Fig. 1a). Importantly, TF is fully active only as part of a
molecular complex tethered within a phospholipid mem-
brane. Huang and coworkers [3] constructed a truncated,
soluble form of TF (sTF), which, because of its solubility,
has minimal coagulation-inducing properties when adminis-
tered free in the circulation. They linked the sTF to a bis-
pecific antibody which recognizes both the sTF molecule
and a second molecule which is present on the cell surface
— in this case a class II molecule of the major histocompati-
bility complex (MHC; Fig. 1b). The group had previously
shown that, when interferon-g-expressing neuroblastoma
cells are implanted in vivo as progressively growing
tumours, the endothelial cells lining the blood vessels
within these tumours showed greatly enhanced expression
of the MHC class II molecule which, significantly, is absent
from normal endothelial cells lining blood vessels in
nontumour cells in vivo. So, the pieces were in place to
provide an experimental model in which a targeting mole-
cule — the antibody — with specificity for a marker known
to be expressed specifically on the tumour blood vessel
endothelium — the MHC class II molecule — was linked
to a molecule which could induce clot formation when
immobilized on a cell surface, namely sTF (Fig. 1).
When the cytokine-expressing neuroblastoma cells were
implanted as tumours into mice which were then treated
systemically with the antibody–sTF complex — which
the authors named the ‘coaguligand’ — histologically
observable thromboses were induced within the growing
tumours and, by 72 hours after administration, the entire
central region of the treated tumours was necrotic (Fig. 2).
Animals that received tumour cells but no coaguligand
showed no such anti-tumour effects. These histological
observations also translated into therapeutic benefits:
mice with large, established tumours underwent complete
(38%) or substantial partial (50%) regressions when treated
with coaguligand. Some small anti-tumour effects were
also seen in mice treated with sTF alone, an effect attrib-
uted to the residual thrombogenic effects of the soluble
molecule by itself. However, no thrombi were detectable
in various other nontumour tissues in the mice treated
with coaguligand or sTF, showing that this approach is
potentially highly tumour-specific and, therefore, safe.
Clearly several problems have to be resolved before this
system becomes therapeutically useful — not least the
identification of surface markers which are expressed
specifically on the endothelial cells of blood vessels sup-
plying human tumours. Only then will it be possible to
target soluble clotting factors to tumours whilst preserving
the free flow of blood throughout other body sites. In this
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(b) Binding of coaguligand to tumour blood vessels causes clot 
      formation and 'starves' the tumour cells. 
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respect, it is worth noting that tumour endothelial cells are
known to express several molecules, such as the receptor
for vascular endothelial cell growth factor (VEGF), which
are normally absent from quiescent endothelium and
which might allow coaguligand-mediated clot targeting.
A second recent report which gives hope for effective anti-
angiogenic targeting comes from Judah Folkman’s
laboratory [4] and has an air of deja vu about it. Two years
ago, the elegant and dramatic discovery of angiostatin
from Folkman’s laboratory [5] was reported in these pages
[6]. Angiostatin, a 342 amino-acid peptide, is an internal
proteolytic fragment of plasminogen, is strongly anti-
angiogenic in vitro, and can suppress the growth of Lewis
lung carcinoma metastases in tumour-bearing mice [5].
One of the many fascinating, but unanswered, questions
raised by its discovery was whether angiostatin — and
particularly the way in which it is produced from plas-
minogen in vivo — is one of a kind, or whether it heralded
a new, general phenomenon whereby molecules could be
readily generated from pre-existing, larger precursors that
have completely separate activities. Now, with the
description of a novel molecule christened endostatin, it
seems that we have the answer.
Endostatin emerged from a screen of material, released
from a hemangioendothelioma cell line, which could
inhibit the proliferation of endothelial cells in vitro. The
biological activity, which was clearly separate from angio-
statin, was purified to homogeneity as a 20 kDa protein.
Microsequencing of the protein revealed identity to an
internal fragment of collagen XVIII (Fig. 3). The coding
sequence for the peptide fragment was expressed in both
bacterial and insect cell expression systems and the
baculovirus-expressed endostatin behaved very similarly
to the 20 kDa activity purified from the cell line and was a
very effective inhibitor of angiogenesis in vitro [4].
Interestingly, on purification, the bacterially expressed
protein was insoluble, but it could move slowly into
solution and was effective in the anti-angiogenic assay.
Although this property was initially problematic for testing,
Folkman’s group used it to provide a slow-release “biode-
pot” of endostatin, by implanting the insoluble protein in
vivo and allowing it to solubilize slowly. With this method
of drug delivery, endostatin was able to inhibit the growth
of both primary tumours and metastases of lung carcinoma
cells in vivo and, remarkably, well- established tumours of
several histological types could be induced to regress as
long as endostatin therapy was maintained. The induction
of tumour regression and chronic dormancy is very reminis-
cent of the properties of angiostatin [5,7]. These results
offer promise of a kind rarely seen in cancer therapeutics —
activity against a broad spectrum of primary tumour types
combined with the ability to cause shrinkage of large, estab-
lished growths. 
Although the properties of angiostatin and endostatin are
phenotypically very similar, there is no clear indication yet
as to whether they exert their effects in the same way bio-
chemically. This is not a trivial point. The history of anti-
cancer therapeutics has been plagued by the discovery of
active compounds followed by the development of
tumour populations resistant to them, which led to the
paradigm of combination therapies for cancer. The discov-
ery of a molecular companion for angiostatin offers the
chance of using combinations of anti-angiogenic therapies.
Thus, if a tumour is found to be resistant to angiostatin it
may be that it is sensitive to endostatin — or vice versa.
Similarly, tumours which produce a certain spectrum of
proteases may not be able to release angiostatin from its
precursor molecule plasminogen; however, the same
tumour may produce the proteases required to liberate
endostatin from collagen XVIII. The identification of the
biochemical mechanisms used by these molecules to
inhibit endothelial cell proliferation, and the possibilities
of their use in combination, will be keenly awaited.
Given the similarities of the properties of endostatin and
angiostatin, the real significance of the new Cell paper [4] is
not so much what endostatin does but where it comes from.
The genealogy of angiostatin and endostatin suggests that
multiple extra layers of biological information can be stored
in the tertiary structure of pre-existing proteins, and that
proteolysis may be a mechanism by which that informa-
tion can be retrieved (Fig. 3). Although proteolytic cleav-
age has long been known to be a way that latent activities
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of enzymes can be activated, these ‘pro-proteins’ have
usually been recognized only as precursors of the active
species. In contrast, here we have molecules such as plas-
minogen and collagen XVIII, which are already serving
defined roles, from which can be released internal frag-
ments  with completely separate activities. As with many
of the most interesting studies, these findings raise many
further questions. How many more molecules contain
extra functions within their three-dimensional structures?
Can internal fragments of this type have activities other
than as angiogenesis inhibitors? Are the activities of angio-
statin and endostatin relevant in vivo in the context in
which they have been found, or do they have other roles
that have not yet been identified because of the nature of
the assays used to date? 
Given the extensive ends to which tumours have gone to
ensure a continued, and expanding, supply of blood, the
results of O’Reilly et al. [4] are surprising in that they
suggest that tumours are simultaneously shooting
themselves in the foot. Tumour cell invasion, leading to
metastasis, is promoted by the secretion of various
proteases by expanding tumours [8]. These proteases
digest the stroma around the tumour, allowing expansion
of the cells into the surrounding areas and, eventually, into
the blood stream for metastatic dispersal [9]. Recently,
angiostatin has been shown to be produced by the
cleavage of plasminogen by a serine protease released
from (prostate) tumour cell lines [10]. This raises the
intriguing prospect that the tumour cells themselves
secrete proteases which, on the one hand, promote their
malignant potential whilst simultaneously checking their
angiogenic and proliferative capacities. 
What could be the evolutionary origins of this pathway, in
which it appears that the body is fighting back against its
malignant foe? It is tempting (and somewhat comforting)
to speculate that here is a very elegant evolutionary twist,
in which biology has devised a way to use the tumour’s
aggressiveness (secretion of proteases) against itself.
Alternatively, the significance of these molecules in the
control of tumorigenesis may be purely coincidental and
their true function remains to be identified.
As elegant and effective as the coaguligand study of Huang
and colleagues [3] is, the discovery of angiostatin [5], and
now endostatin [4], seems to have more immediate  clinical
applicability. Both the coaguligand and endostatin can
shrink large animal tumours but, unlike the targeted clot-
ting approach, endostatin is naturally derived from tumours
without the need for molecular manipulations. In addition,
it maybe that the angiostatin and endostatin examples are
showing us that we should be searching for a whole new
stratum of biological information in which the ‘first degree’
tertiary structure of a protein may be further divisible into
(multiple) ‘second degree’ tertiary structures that have
completely separate associated biological functions. These
studies seem likely to prove major contributions to under-
standing both potential cancer therapies and fundamental
physiology.
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